Publikationen, an denen er mitarbeitet Jordi Sierra Gil (75)

2022

  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

  2. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2020

  1. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

    European Journal of Haematology, Vol. 105, Núm. 2, pp. 138-147

  2. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (Bone Marrow Transplantation, (2020), 55, 4, (681-694), 10.1038/s41409-019-0718-7)

    Bone Marrow Transplantation

  3. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

    Bone Marrow Transplantation, Vol. 55, Núm. 3, pp. 641-648

2019

  1. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia

    Leukemia Research, Vol. 85

2018

  1. CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome 

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 5, pp. 964-972

  2. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

    PLoS ONE, Vol. 13, Núm. 6

  3. Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia

    Cancers, Vol. 10, Núm. 11

  4. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

    Medical Oncology, Vol. 35, Núm. 6

2017

  1. NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients

    Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014

2016

  1. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 3, pp. 584-588

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

  2. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival

    Journal of Pathology, Vol. 235, Núm. 3, pp. 445-455

  3. Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML

    American Journal of Clinical Pathology, Vol. 144, Núm. 3, pp. 484-492

  4. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT

    Bone Marrow Transplantation, Vol. 50, Núm. 1, pp. 121-126

  5. Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: Results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH)

    Transplant Infectious Disease, Vol. 17, Núm. 2, pp. 221-233

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318

2013

  1. Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 4, pp. 597-601

  2. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

    Haematologica, Vol. 98, Núm. 4, pp. 526-532